目的:探究硝苯地平控释片对高血压伴高尿酸血症的肾病患者的治疗效果.方法:选取2020年3月至2021年3月在菏泽市立医院就诊的60例高血压伴高尿酸血症的慢性肾脏病1-2期患者为研究对象,随机分为观察组(30例)和对照组(30例),两组基础治疗相同,控制血压:观察组为硝苯地平控释片治疗,对照组为酒石酸美托洛尔治疗.探究两组患者治疗后的血压、血肌酐、尿素氮、胱抑素c、24h尿蛋白定量、血尿酸和不良反应发生率.结果:观察组患者治疗后的血压、24h尿蛋白定量、血尿酸显著低于对照组,差异有统计学意义(＜0.05);“,”Objective:Toexplore the therapeutic effect of nifedipine controlled-release tablets on nephropathy patients with hypertension and hyperuricemia. Methods:Sixty patients with chronic kidney disease stage 1-2 with hypertension and hyperuricemia who were treated in Heze Municipal Hospital from March 2020 to March 2021 were selected as the research objects, and they were randomly divided into observation group (30 cases) and control group (30 cases), and the two groups had the same basic treatment,Blood pressure control: the observation group was treated with nifedipine controlled-release tablets, and the control group was treated with metoprolol tartrate. After treatment, blood pressure, Serum creatinine, urea nitrogen,cystatin C, 24h urine protein level, blood uric acid and the incidence of adverse reactions in 2 groups were investigated.Results:After treatment, blood pressure, 24h urinary protein level and blood uric acid in observation group were significantly lower than those in control group, with statistical significance ( ＜0.05).There was no statistical significance in serum creatinine, urea nitrogen and cystatin C in observation group after treatment compared with control group ( ＞0.05). Conclusion:Nifedipine controlled-release tablets in the treatment of nephropathy patients with hypertension and hyperuricemia is beneficial to control the patient\'\'s blood pressure. and have the effect of reducing blood uric acid level and reducing proteinuria, with high safety.